Form 4: Sight Sciences CLO Granted 115,920 RSUs

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, was granted 115,920 restricted stock units valued at $750,000.

Summary

• Jeremy B. Hayden, Chief Legal Officer of Sight Sciences, Inc. (SGHT), was granted 115,920 restricted stock units (RSUs).
• The grant, made under the Issuer's 2021 Incentive Award Plan, is valued at $750,000.
• The RSUs vest in 16 equal quarterly installments, commencing March 31, 2026, and continuing through December 31, 2029.
• Vesting is contingent upon Mr. Hayden's continued service to Sight Sciences through each vesting date.
• Each RSU represents a contingent right to receive one share of Sight Sciences' common stock.
• The number of RSUs granted was determined by dividing $750,000 by the closing price of the common stock on the grant date, February 3, 2026, which implies a closing price of approximately $6.47 per share.
• Following this transaction, Mr. Hayden beneficially owns 383,531 shares, comprising 75,562 shares of Common Stock and 307,969 unvested RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive, routine executive compensation event that aligns the Chief Legal Officer's interests with long-term shareholder value through equity incentives, without introducing new material risks or opportunities.

Positives

• The grant of restricted stock units aligns the Chief Legal Officer's interests with long-term shareholder value, incentivizing continued service and performance.
• The equity grant is a standard component of executive compensation, reflecting a commitment to retaining key management.

Future Outlook

The RSU grant, with its multi-year vesting schedule extending through December 2029, indicates an expectation of continued service from the Chief Legal Officer and a long-term incentive structure for executive retention and performance.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units, are a prevalent compensation mechanism within the medical device and ophthalmology sectors. These grants are designed to align the long-term interests of executives with those of shareholders, fostering sustained performance and retention in a competitive industry.

Comparison to Industry Standards

• Equity-based compensation, particularly through RSU grants, is a standard practice for executive remuneration across the healthcare and technology industries, including companies comparable to Sight Sciences in the ophthalmic medical device space.
• The structure of vesting over several years is typical for such grants, aiming to incentivize long-term commitment and performance, similar to practices observed at companies like Glaukos Corporation or Ivantis, Inc. (acquired by Alcon).

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced alignment of executive incentives with long-term company performance and value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term strategic goals.

Next Steps

• Jeremy B. Hayden's continued service to Sight Sciences, Inc. is required for the RSUs to vest according to the established quarterly schedule.

Key Dates

Recommendation

This Form 4 reports a standard equity grant to an executive, which is a routine compensation event and does not provide new material information to warrant a change in investment recommendation. It primarily serves to align executive incentives with long-term company performance, which is generally a positive but not a catalyst for a rating change.

Keywords

Sight Sciences, SGHT, Restricted Stock Units, RSUs, Insider Transaction, Executive Compensation, Form 4, Jeremy Hayden, Equity Grant